Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.46 |
| ▸ | ALOX15B | O15296 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264767 | 1.00 | NISCH (0.54) | NISCHESR1ESR2TTRALOX15 | |
| SCHEMBL10534369 | 0.86 | ESR1 (0.50) | NISCHESR1ESR2TTRALOX15 | |
| SCHEMBL7531682 | 0.86 | ESR2 (0.71) | NISCHESR1ESR2TTRALOX15 | |
| SCHEMBL22201929 | 0.84 | ALOX15 (0.46) | NISCHESR1ESR2TTRALOX15 | |
| SCHEMBL6204486 | 0.82 | CYP19A1 (0.51) | NISCHESR1ESR2TTRALOX15 | |
| SCHEMBL11337871 | 0.82 | ALOX15 (0.64) | NISCHESR1ESR2TTRALOX15 | |
| SCHEMBL29377562 | 0.81 | NISCH (0.44) | NISCHESR1ESR2TTRSIGMAR1 | |
| SCHEMBL16536569 | 0.81 | GRIN2B (0.41) | NISCHSIGMAR1HTR1AGRIN2B | |
| SCHEMBL16547285 | 0.81 | GRIN2B (0.41) | NISCHSIGMAR1HTR1AGRIN2B | |
| SCHEMBL10536098 | 0.80 | CYP19A1 (0.50) | NISCHESR1ESR2TTRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005744-A | Quality marker for preventing and treating kidney-yang deficiency by using medicinal and edible formula composition, and preparation method and application thereof | 广西壮族自治区中医药研究院 | 2026-05-12 | — | — | CN | claimed |
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| US-12474287-B2 | Detection device and methods of use thereof | AMULET, INC. (US) | 2025-11-18 | — | — | US | claimed |
| CN-119192161-B | High-isoflavane compound extracted from radix Ophiopogonis fibrous root and having tyrosinase inhibitory activity, and preparation method and application thereof | 云南省药物研究所 | 2025-02-25 | — | — | CN | claimed |
| CN-119192161-A | High-isoflavane compound extracted from radix Ophiopogonis fibrous root and having tyrosinase inhibitory activity, and preparation method and application thereof | 云南省药物研究所 | 2024-12-27 | — | — | CN | claimed |
| US-20240316118-A1 | ANTIVIRAL NASAL SPRAY FLAVONOIDS?BEE PROPOLIS | MCCAFFREY STEPHEN MARK (AU) | 2024-09-26 | — | — | US | claimed |
| US-20240219336-A1 | FOOD ALLERGEN DETECTION DEVICE AND METHODS OF USE THEREOF | AMULET, INC. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240122894-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-04-18 | — | — | US | claimed |
| CN-115177604-B | Application of astragalus isoflavan in preparing medicament for protecting biological stability of BMSCs | 甘肃中医药大学 | 2024-02-06 | — | — | CN | claimed |
| EP-4259614-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | National University of Singapore (SG) | 2023-10-18 | — | — | EP | claimed |
| CN-115177604-A | Application of astragalus isoflavane in preparation of medicines for protecting biological stability of BMSCs | 甘肃中医药大学 | 2022-10-14 | — | — | CN | claimed |
| CN-114632085-A | Application of ginseng and astragalus extract and active components thereof in preparing medicine for treating or preventing central nervous inflammation | 中国科学院上海药物研究所 | 2022-06-17 | — | — | CN | claimed |
| WO-2022124994-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-06-16 | — | — | WO | claimed |
| CN-114028384-A | Application of licorice isoflavane derivative in preparation of medicine for preventing, relieving or/and treating pruritus | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2022-02-11 | — | — | CN | claimed |
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-04-03 | — | — | US | claimed |
| CN-1400904-A | Selective estrogen receptor modulators in combination with estrogens | ENDORECH INC (CA) | 2003-03-05 | — | — | CN | claimed |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2003-02-27 | — | — | US | claimed |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2002-12-26 | — | — | US | claimed |
| EP-1251855-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | Endorecherche, Inc. (CA) | 2002-10-30 | — | — | EP | claimed |
| WO-2001054699-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS IN COMBINATION WITH ESTROGENS | ENDORECHERCHE, INC. (CA) | 2001-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065008-A1 | Selective estrogen receptor modulators in combination with estrogens | ESR1, BRCA1, KISS1R | NISCH 3597/4885ESR1 1/4885ESR2 8/4885 |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | NISCH 3422/4885ESR1 2/4885ESR2 8/4885 |
| US-20240122894-A1 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | ERG28, MGAM, CTRB2 | NISCH 115/4885ESR1 3763/4885ESR2 3839/4885 |
| US-20030040510-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | NISCH 3422/4885ESR1 2/4885ESR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.